Literature DB >> 25636973

Endoscope-assisted intraoral excision of osteochondroma of the mandibular condyle.

Divya Singh1, Pushkar Gadre2, Kiran Gadre3, Sneha Setiya1.   

Abstract

Osteochondroma (OC) is one of the most common bony lesions of the skeleton. It is rare in the maxillofacial region and reported infrequently in the literature. This lesion is considered the most common of benign tumors of the temporomandibular joint. It is usually associated with the coronoid, followed by the condyloid process. OC can affect any bone formed from cartilage and can arise spontaneously or as a result of osseous trauma. It usually protrudes from the surface of bone and is covered with cartilage. Most condylar OCs present as progressive limitation of mandibular movements, facial asymmetry, malocclusion, pain, and deviation in mouth opening. Extraoral approaches to the OCs, which are usually located on the medial pole of the condyle, provide ease of accessibility, although there is an inherent likelihood of damage to the facial nerve and scarring. The use of a transoral endoscope-assisted conservative approach for the removal of OCs produces the desired favorable esthetic and functional results.
Copyright © 2015 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25636973     DOI: 10.1016/j.joms.2014.10.022

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  2 in total

1.  A modified approach from the edge of the tragus in the surgical treatment of mandibular condyle fractures.

Authors:  X Lin; X-Y Liu; X-P Huang
Journal:  Ann R Coll Surg Engl       Date:  2018-08-16       Impact factor: 1.891

2.  A new method for individual condylar osteotomy and repositioning guides used in patients with severe deformity secondary to condylar osteochondroma.

Authors:  Lei Qi; Ningning Cao; Weiwen Ge; Tengfei Jiang; Linfeng Fan; Lei Zhang
Journal:  Orphanet J Rare Dis       Date:  2021-01-30       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.